ADM2

Across TCGA pan-cancer cohorts, ADM2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADM2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ADM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADM2 expression acts as an unfavorable survival marker.

BRCA and SCLC are the cancer types where ADM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.120	0.578	.020	12	view →
SCLC	OS	Median	All	0.279	0.788	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ADM2–BRCA (OS)

Open the BRCA breakdown →